Moreover, trial NCT00005813 investigates the use of LAK cells combined with the MDX477 bispecific antibody for intra-tumoral injection in patients with GBM expressing epidermal growth factor receptor (EGFR), aiming to enhance the targeting of tumor cells with bispecific antibodies. Here, EGFR is linked to glioblastoma.